Quantcast
Home > Quotes > SYN

Synthetic Biologics, Inc. Common Stock (SYN) Quote & Summary Data

SYN 
$2.75
*  
0.20
7.84%
Get SYN Alerts
*Delayed - data as of Aug. 17, 2018  -  Find a broker to begin trading SYN now
Exchange:AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
38
Today's High / Low
$ 2.85 / $ 2.55
Share Volume
127,716
90 Day Avg. Daily Volume
633,614
Previous Close
$ 2.55
52 Week High / Low
$ 36.7506 / $ 2.45
Market Cap
353,558,882
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.91

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
Aug. 13, 2018
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
127,716
90 Day Avg. Daily Volume:
633,614

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -5.94

Trading Range

The current last sale of $2.75 is 12.24% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.85 $ 36.7506
 Low: $ 2.55 $ 2.45

Company Description (as filed with the SEC)

We are a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. Our lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).  ... More ...  


Risk Grade

Where does SYN fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info